Health TrialsbyHealthPanel

Brain Ultrafast Ultrasound Imaging

ConditionCHD - Congenital Heart Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-2
SponsorUniversity Hospital, Bordeaux

About this trial

Congenital heart defects affect 1 in 100 births in France, with rising prevalence due to better care. Despite improved survival, 40% of children post-surgery face neurological impairments, and some of them show brain lesions. Causes include heart defects, genetic syndromes, and surgeries. Some heart defects and support systems increase cerebral risks. Monitoring cerebral perfusion is difficult to assess but emerging ultrafast ultrasound offers real-time, non-invasive blood flow insights.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Every patient under 2 years old any sex or gender hospitalised in the congenital heart disease unit of the intensive care and anaesthesia for cardiovascular surgery, CHU de Bordeaux.

Open anterior fontanella

congenital heart disease

cardiac shock necessitating mechanical circulatory support.

Disqualifiers

Anechoic

Allergy to echocardiography gel.

Trial population

Every patient, under two years old, receiving a transcranial Doppler in routine care in our CHD unit of intensive care and anaesthesiology for cardiovascular surgery department.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Ultrafast ultrasound (UFUS)

    Other intervention

    Ultrafast ultrasound imaging(UFUS), ultrasound images at a very high rate, using a Verasonics system (ultrasound open platform).

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Patient receiving a transcranial Doppler1 intervention

Trial outcomes

Primary outcomes

1

Cerebral blood volume variation

Depending on stage of medico-surgical treatment

Time frame
at baseline
2

Cerebral blood volume variation

Depending on hemodynamic or ventilatory situation, and exposure to vasoactive or neuroactive drugs.

Time frame
at baseline

Secondary outcomes

1

Evolution of Arterial blood pressure

Time frame
at baseline
2

Evolution of central venous blood pressure

Time frame
at baseline
3

Evolution of left atrial pressure

Time frame
at baseline
4

Evolution of SpO2

Time frame
at baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Bordeaux

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: